Unfortunately, prostate cancer screening strategies with PSA and digital rectal exam are not specific for high‐risk disease and often lead to diagnosis and overtreatment of lower risk tumors that may not impact survival. This evidence concerns the gene KLK3 and prostate carcinoma.